endothelial cell adhesion to the extracellular matrix during neovascularization.
Some of the most advanced angiogenesis inhibitors currently being evaluated in clinical trials are matrix metalloproteinase (MMP) inhibitors. Marimastat (British Biotech, Annapolis, MD, USA) was the first MMP inhibitor to be involved in rigorous clinical trials. In a phase III study incorporating 400 patients with advanced pancreatic cancer, marimastat showed no single therapy benefit over gemcitabine, the 'drug of choice'. Nevertheless, marimastat at 25 mg twice a day was as effective as gemcitabine and appeared to have an improved therapeutic index at lower doses (5 mg or 10 mg) with fewer side-effects. It is clear that further studies of marimastat will be needed before a complete assessment of the efficacy, tolerability and dose regimen can be made. To this end, nine randomized controlled studies of marimastat in a range of solid tumours (pancreatic, non-small-cell lung, breast cancers) are ongoing and the current expectation is that these data will be available within the next 3 years.
Other metalloproteinase inhibitors in advanced trials are Bay 12-9566 (Bayer, West Haven, CT, USA) and Ag3340 (Agouron, La Jolla, CA, USA). Several international phase III clinical trials using Bay 12-9566 against solid tumours including lung, ovarian and pancreatic cancer are being conducted. In addition, the National Cancer Institute (NCI) is currently performing phase I studies designed to evaluate a possible use of Bay 12-9566 in combination regimens with doxorubicin, fluorouracil or low-dose leucovorin. There are several phase III clinical trials underway to evaluate AG3340 alone or in combination with the anticancer drugs paclitaxel/carboplatin for the treatment of non-small-cell lung cancer and mitoxantrone/prednisone for hormone-refractory prostate cancer. It has been shown that the anti-tumour efficacy of AG3340 is associated with maintenance of a minimum plasma concentration but not total daily dose, exposure or peak plasma concentrations (Brekken et al, 1999) .
Attempts to abrogate the angiogenic activity of vascular endothelial growth factor (VEGF) have varied from inactivation of VEGF itself by using, for example, antibodies (Mordenti et al, 1999) or soluble receptors to specific inhibition of the VEGF receptor tyrosine kinase (Lin et al, 1998) . The latter includes ZD4190, an anilino quinazoline derivative that specifically inhibits the VEGF receptor 2 (KDR) tyrosine kinase and has shown widespread anti-tumour activity in in vivo animal models following oral administration Ogilvie et al, 1999) . Another VEGF receptor tyrosine kinase inhibitor showing much promise is SU5416 (Sugen Inc., CA, USA).
The interaction of the angiogenic endothelial cell with extracellular vitronectin mediated via the α v integrin is crucial during angiogenesis. It follows that antibodies to the α v β 3 integrin are strongly anti-angiogenic and mouse monoclonals have been humanized as 'Vitaxin' to permit clinical trials. Preliminary results have shown stable disease or shrinkage in eight of 14 late-stage cancer patients. No side-effects have been observed so far (Eliceiri and Cheresh, 1999) .
ANGIOSTATIN AND ENDOSTATIN, EMERGING ANGIOGENESIS INHIBITORS
An area of intense current interest is that of potent naturally occurring inhibitors of angiogenesis being encrypted within larger molecules with no angiogenic activity but having other functions. Proteolytic cleavage releases the active material. Such molecules include angiostatin, a fragment of plasminogen ; endostatin, a fragment of collagen type 18 (O'Reilly et al, 1997); a 16 kDa fragment of prolactin; and a fragment of thrombospondin. Attention has been most focused on endostatin, which is able to bring about successive waves of substantial tumour
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One year ago, a front page article in the New York Times (Kolata, 1998) initiated speculation that cancer could be treated with angiostatin and endostatin. That article, and coverage by other media, generated intense public interest in angiogenesis inhibitors and a subsequent controversial and emotional debate (Wadman, 1998; Cohen, 1999; Harris, 1999; Rowe, 1999) . The controversy was fueled as studies on endostatin in laboratories outside Boston were unable to confirm the endostatin results, showing only a slight growth retardation of Lewis lung carcinoma (a difficult tumour to treat with chemotherapeutic agents) in mice. Members of the NCI went to Folkman's laboratory in Boston to clarify why the results differed from those in the original study. In Boston, subsequent results were consistent with previous experiments, showing striking inhibition of tumour growth. Variations in experimental techniques between the two laboratories, such as injecting mice, as well as storage, handling and purification of endostatin, are assumed to have been responsible for the previously observed lack of agreement in results.
The NCI's success with mouse endostatin -just a few months after it had been announced publicity that it could not replicate the results -allowed the Institute to initiate plans for the testing of human endostatin in patients, pending full-scale toxicology studies. In early fall of 1999 two sites were expected to conduct phase I studies with approximately 15-25 patients each in patients with solid tumours, including lung, breast, colon and prostate carcinoma. To launch clinical studies it has been necessary to scale up the production of endostatin. By applying a yeast expression system it is now possible to produce soluble human endostatin at quantities sufficient for clinical assessment in man (Sim et al, 1999) .
Animal studies with angiostatin and endostatin have so far been only with transplanted tumours, which show a different biology when compared to organ-specific, spontaneous tumours and are not necessarily accurate predictors of what will happen in natural human cancers. Thus, a transgenic mouse model of pancreatic islet carcinogenesis (RIP1-Tag2) was used as a model to examine the effect of several angiogenesis inhibitors on multistage tumorigenesis (Bergers et al, 1999) . Apart from endostatin, angiostatin and a combination of both, AGM-1470 (TNP470; a fumagillin derivative which is thought to inhibit endothelial cell proliferation by irreversible binding to the enzyme methionylaminopeptidase-2) (Sin et al, 1997) and BB-94 (batimastat; a matrix metalloproteinases inhibitor) (Talbot and Brown, 1996) were tested for their anti-angiogenic potency in a prevention, intervention and regression trial in the RIP-Tag mice. The four angiogenesis inhibitors examined showed distinct efficacy profiles varying from about 60% to 85% depending on the stage of carcinogenesis being targeted. However, none of the agents tested completely prevented the angiogenic switch, blocked the growth of small tumours, or fully resolved lethal tumour burden. These results suggest that the prevention and treatment of human spontaneous organ-specific malignancies with anti-angiogenic agents is going to be more complex and difficult than was originally anticipated. For example, it is not possible to predict if human tumours are going to respond in vivo to human endostatin as do mouse tumours to mouse endostatin. The story of angiostatin and endostatin shows that much has yet to be learned about anti-angiogenic agents. Several years after the discovery of angiostatin and endostatin, recent reports began to give insight into the mechanism of anti-angiogenic action of those agents. Angiostatin has been shown to inhibit matrix-enhanced plasminogen activation, resulting in reduced invasive activity ). Angiostatin's antiproliferative effect was reported to be mediated by binding to the α/β-subunits of ATP synthase . The last observation is noteworthy as it might be possible to develop small molecules that could mimic angiostatins effect on the ATP synthase-binding protein. Smaller molecules would reduce the problem of immunogenicity, might be more easy to synthesize and might be taken orally. Less is known about the mechanism of action of endostatin but it is believed to induce apoptosis of endothelial cells by reducing anti-apoptotic proteins like Bcl-2 (Dhanabal et al, 1999b) .
OTHER ANGIOGENESIS INHIBITORS
It may not be the agents currently in trials that work best in the end. Several hundred angiogenesis inhibitors have been identified and the list is mushrooming, including exotic substances like those extracted from green tea (Cao and Cao, 1999) . It is possible that some of the newly identified agents are going to be more potent than the currently known drugs. Although the chance of an antiangiogenic agent moving into standard medical practice is estimated to be in the order of 1:10 000, a 'gold-rush' atmosphere has developed to detect or develop such a compound as the potential market is comparable to antibiotics and chemotherapeutics, that is of the order of billions of dollars per year (Brem, 1998) .
Some previously known drugs have also been shown to be angiogenesis inhibitors. For example thalidomide, a drug with a tarnished past, achieved a comeback after its antiangiogenic properties were identified. (D'Amato, 1994) , and it is almost no surprise that aspirin with its pleiotropic effects has been identified as an angiogenesis inhibitor (Tsujii et al., 1998) .
ANTI-ANGIOGENESIS AND CONVENTIONAL ANTICANCER THERAPIES
Many traditional cancer therapies probably have an antiangiogenic component. Thus, chemotherapeutic agents such as the taxanes and camptothecins have anti-angiogenic properties that may, at least in part, account for their efficacy as anti-tumour agents (Belotti et al, 1996) . It is possible that low-dose standard chemotherapeutic regimens may inhibit angiogenesis without being cytotoxic to the tumour. Anti-oestrogen therapy for the prevention or adjuvant treatment of breast cancer may also be mediated by affecting vascularity as tamoxifen has been shown to inhibit angiogenesis ( Van der Schaft et al, 1999) .
Further evidence for the anti-angiogenic activity of conventional as well as experimental cancer therapies comes from a growing number of studies that have shown that damage of blood vessels precede or accompanies tumour regression after radiation therapy, hyperthermia, photodynamic therapy or administration of a variety of biological response modifiers such as interferon, tumour necrosis factor, interleukins or endotoxin (Baillie, 1995) . Finally, it is also known that many oncogenes modulate the expression of angiogenic factors, such as VEGF, and thus therapies targeting these genes may also be effective through the inhibition of angiogenesis (Rak et al, 1995) .
DESIGNING CLINICAL TRIALS OF ANGIOGENESIS INHIBITORS
There are important differences between anti-angiogenic clinical trials and traditional trials of cytotoxics (Kerbel and Pluda, 1999) . In phase I trials most of the anti-angiogenic agents have been exceptionally well tolerated, lacking many of the side-effects associated with conventional cancer chemotherapies (neutropenia, nausea and vomiting etc.) . Due to this lack of measurable toxicity, it has been difficult to define the maximum tolerated dose and to identify a recommended drug dose. Further, in phase II studies it has proven a challenge to assess the effectiveness of angiogenic drugs. These relate to the observations that most of those agents do not necessarily cause tumour shrinkage but induce tumour dormancy leading to stable disease. Exceptions are agents used for vascular targeting (Huang et al, 1997 ) and the more recently described natural inhibitors, such as angiostatin and endostatin. Measuring time-to-progression is a parameter to determine stable disease but it tends to be a heterogeneous time point, with great interpersonal variation (Kerbel and Pluda, 1999) . Two methods have, however, been usefully applied to assess responsiveness to anti-angiogenic therapy: (i) measurement of serum levels of angiogenic peptides and (ii) magnetic resonance imaging to detect contrast uptake and washout in tumours. Due to the difficulties of phase II trials, it seems likely that many anti-angiogenesis drugs will proceed rapidly from phase I to phase III.
CONCLUSIONS
For many years the perceived role for angiogenesis inhibitors in the clinic was either in the adjuvant situation or in combination with conventional cytotoxic's permitting use of lower doses of the latter. Recently, however, the arrival of new angiogenesis inhibitors such as endostatin that achieve substantial tumour regression points to a potentially greater role for angiogenesis inhibitors in oncology. Clinical application of anti-angiogenic agents looks an increasingly realistic prospect. Clearly, the next few years will see a period of intense research into the clinical potential for inhibitors of angiogenesis in the treatment of cancer.
